The HIV epidemic in this region is generalised but young women, men who have sex with men, transgender people, sex workers, prisoners and people who inject drugs are at an increased vulnerability to infection.
The international community has been quick to respond to this catastrophe: George Mobiot, Hanging on to the profits from AidsThe Guardian, August 5, In the middle ofthe interests of the pharmaceutical industry via lobbying through Vice President Al Gore had resulted in the US actually threatening South Africa with trade sanctions for trying to develop generic and cheaper drugs to fight AIDS etc.
However, there was nothing illegal about what South Africa was doing, and so the the actions of the pharmaceutical industry drew a lot of criticism that they were concerned mostly about the impacts to their sales. While the World Trade Organization's Trade-Related Aspects of Intellectual Property Rights TRIPS agreement is controversial for many other aspects in its provisions, it still allows the ability for South Africa to produce cheaper drugs due to national emergencies and because it is for public, non-commercial use.
Not coincidentally, it is also one of the few diseases that remain a threat to First World countries. Or is it, given that the underlying goal for most pharmaceutical companies is " profit at all costs "?
The way that various international trade agreements are negotiated and dominated has not been atypical of this, either. Also, now that there is a possibility that the economy of various countries in Africa will be affected, the US will refrain from imposing sanctions on Sub-Saharan governments.
Back to top But Pharmaceutical companies continue the pressure However, that has not stopped the pharmaceutical industry continuing to pursue its interests. Some 40 such companies took South Africa to court beginning of Marchover language in the Medicines Act which would allow for generic production and parallel importing of affordable AIDS drugs.
The public outrage around the world that resulted from these companies trying to do such a thing while people were dying led to them drop their case in April, In fact, while there have been a number of apparent successes by pressure groups crying for more justice, as Jamie Love suggests, a lot of the resulting actions by pharmaceutical companies and supportive governments has been "just slick humanitarian-flavored spin".
For example, he points out that: In almost every case, as he points out, they are simply dropping prices or just giving the pills away rather than granting licenses for local manufacture.
And he doesn't believe that corporate largess alone will be enough to stave off one of the worst epidemics in human history. The issue of maintaining control over who can manufacture the drugs and their costs, are forms of dependency that assure inequality. This is described more in the poverty section of this web site.
While, as the French paper, Le Monde reports, Pfizer and 10 others have promised to give the US Congress General Accounting Office all the data it needs to check drug prices, another issue has also emerged, which is the benefits that some universities get from the patents: The world's largest pharmaceuticals company, Pfizer, and 10 others have promised to give the US Congress General Accounting Office all the data it needs to check drug prices.
Like Europe, the US is concerned about the massive profits made by the pharmaceuticals industry. In rich countries, the laboratories' pricing policies are a scam; in poor countries, they are preventing most people from getting treatment.
Stavudine, used to treat Aids, is the perfect demonstration of what is wrong with the system. It hugely profits its makers - and Yale University, where it was researched.
Patenting an invention means nothing without sales. Intwo years after filing its patent 4Yale granted pharmaceuticals giant Bristol-Myers Squibb BMS exclusive rights to exploit its invention.
This "exclusive licence" gave BMS a monopoly in every country where Yale filed its patent:For the past six years, Stephanie Nolen has traced AIDS across Africa, and 28 is the result: an unprecedented, uniquely human portrait of the continent in crisis.
Through riveting, anecdotal stories, she brings to life men, women, and children involved in every AIDS arena, making them familiar. home: the stories: the book: the author: take action: buy the book: readers respond: what's new: contact us. East and Southern Africa is the region hardest hit by HIV.
It is home to % of the world’s population but over half of the total number of people living with HIV in the world ( million people). In 28, Stephanie Nolen, the Globe and Mail’s Africa Bureau Chief, puts a human face to the crisis created by HIV-AIDS in Africa.
She has achieved, in this amazing book, something extraordinary: she writes with a power, understanding and simplicity that makes us listen, makes us understand and care.5/5(1). Once I read Stories of AIDS in Africa, I was able to understand the origin and transmission of the AIDS virus and the crisis it is causing in Africa.
“In Stories of AIDS in Africa, Nolen takes the reader on an emotional journey through the continent as she tells the stories of 28 people fighting HIV/AIDS The Reviews: 9.